Modulation of adiponectin as a potential therapeutic strategy.
Seoul, South Korea. In Atherosclerosis, Apr 2014
Intensive lifestyle modifications and pharmacologic agents, including peroxisome proliferator-activated receptor-γ or α agonists, some statins, renin-angiotensin-aldosterone system blockers, some calcium channel blockers, mineralocorticoid receptor blockers, new β-blockers, and several natural compounds can increase adiponectin levels and suppress or prevent disease initiation or progression, respectively, in cardiovascular and metabolic disorders.
Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).
Messina, Italy. In Pharmacol Res, Mar 2014
Instead, palmitoylethanolamide (PEA) a member of the fatty acid ethanolamine family, is a novel non-steroidal, kidney friendly anti-inflammatory and anti-fibrotic agent with a well-documented safety profile, that may represent a potential candidate in treating CKD probably by a combination of pharmacological properties, including some activity at the peroxisome proliferator activated receptor alpha (PPAR-α).
Biological Rationale for the Use of PPARγ Agonists in Glioblastoma.
Bristol, United Kingdom. In Front Oncol, Dec 2013
There has been interesting preliminary evidence suggesting that diabetic patients receiving peroxisome proliferator-activated receptor gamma (PPARγ) agonists, a group of anti-diabetic, thiazolidinedione drugs, have an increased median survival for glioblastoma.
p53 induces skin aging by depleting Blimp1+ sebaceous gland cells.
More papers using
Los Angeles, United States. In Cell Death Dis, Dec 2013
The reduction in the fat layer may result from the decrease of mammalian TOR complex 1 (mTORC1) activity accompanied by elevated expression of energy expenditure genes, and possibly as compensatory effects, leading to the elevation of peroxisome proliferator-activated receptor (PPAR)γ, an inducer of sebocyte differentiation.